title: Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study.
abstract: BACKGROUND
  Whether percutaneous radiofrequency ablation (PRFA) is as effective as repeat hepatectomy for recurrent small hepatocellular carcinoma (HCC) in the long-term remains unknown.
  
  
  METHODS
  We included 110 patients into this study. Each patient had fewer than three recurrent HCCs, with the largest tumor less than 5 cm in diameter. Sixty-six patients with 88 tumors were treated by PRFA and 44 patients with 55 tumors were treated by repeat hepatectomy.
  
  
  RESULTS
  The 1-, 2-, 3-, 4-, and 5-year overall survival rates after repeat hepatectomy and PRFA were 78.6%, 56.8%, 44.5%, 30.7%, and 27.6%, and 76.6%, 48.6%, 48.6%, 39.9%, and 39.9%, respectively (P = 0.79). The 1-, 2-, 3-, 4-, and 5-year overall survival rates after the initial hepatectomy for the two groups were 95.4%, 79.1%, 65.0%, 50.4%, and 42.9%, and 98.5%, 85.0%, 70.8%, 58.7%, and 55.6%, respectively, (P = 0.18). Subgroup analyses showed that there was no significant difference between the overall survivals of the two groups of patients when the interval of tumor recurrence from the initial hepatectomy was <or=1 year (P = 0.74) or >1 year (P = 0.69), and for recurrent tumor <or=3 cm (P = 0.62) or >3 cm (P = 0.57). Major complications happened significantly more often after repeat hepatectomy than PRFA (30 of 44 versus 2 of 66, P < 0.05). The interval of recurrence from the initial hepatectomy, the diameter of the recurrent tumor and the serum albumin level were significant prognostic factors for overall survival.
  
  
  CONCLUSIONS
  PRFA was as effective as repeat hepatectomy in the treatment of recurrent small HCC. PRFA had the advantage over repeat hepatectomy in being less invasive.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Guangzhou, People's Republic of China.
authors.forename: Hui-Hong
authors.initials: HH
authors.lastname: Liang
authors.forename: Min-Shan
authors.initials: MS
authors.lastname: Chen
authors.forename: Zhen-Wei
authors.initials: ZW
authors.lastname: Peng
authors.forename: Yao-Jun
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Ya-Qi
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Jin-Qing
authors.initials: JQ
authors.lastname: Li
authors.forename: Wan Yee
authors.initials: WY
authors.lastname: Lau
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional; D055815:Young Adult